$ABOS Cashflow Statement | Understand Stock

$ABOS

$2.28 +$0.01 (0.44%) Live

$ABOS Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Statements of cash flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation
Change in fair value of preferred stock tranche rights liability and preferred stock warrant liability
Stock-based compensation expense
Amortization of premiums and accretion of discounts on marketable securities, net
Change in fair value of embedded derivatives
Amortization of right-of-use asset
Non-cash research and development expense
Realized gain on marketable securities
Noncash interest expense
Other noncash expense
Changes in operating assets and liabilities:
Prepaid expenses and other current assets
Other long-term assets
Accounts payable
Accrued clinical trial expenses
Accrued expenses and other liabilities
Finance lease liability
Operating lease liability

Net cash used in operating activities
Cash flows from investing activities
Purchases of marketable securities
Proceeds from maturities and sales of marketable securities
Proceeds from sale of property and equipment
Purchases of property and equipment
Net cash provided by investing activities
Cash flows from financing activities
Proceeds from issuance of common stock, net of issuance costs
Proceeds from Term Loan
Proceeds from exercise of stock options
Proceeds from issuance of Series B milestone shares, net of issuance costs
Proceeds from exercise of Series A-1 warrant
Proceeds from exercise of common stock warrants
Series A -1 Convertible Preferred Stock Warrant Liability
Common Stock Warrants
Total proceeds from exercise of common stock warrants
Payment for financing lease
Payments for financing costs
Payments for deferred offering costs
Repurchase of common shares to pay employee withholding taxes
Net cash (used in) provided by financing activities

Net change in cash and cash equivalents and restricted cash
Cash and cash equivalents at the beginning of the period
Cash and cash equivalents at the end of the period
Cash and cash equivalents and restricted cash at the beginning of the period
Cash and cash equivalents and restricted cash at the end of the period
Supplemental disclosure of cash flow information
Cash paid for income taxes
Cash paid for interest
Right-of-use assets obtained in exchange for finance lease liabilities
Right-of-use assets obtained in exchange for operating lease liabilities
Conversion of convertible preferred stock into common stock upon IPO
Reclassification of preferred stock tranche rights liability upon share issuance
Reclassification of warrant liability upon exercise of preferred stock warrant
Issuance of warrant with Term Loan

Comments